Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 133 articles:
HTML format
Text format



Single Articles


    June 2018
  1. GORI S, Puglisi F, Cinquini M, Pappagallo G, et al
    Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
    Eur J Cancer. 2018;99:9-19.
    PubMed     Text format     Abstract available


  2. DERKS MGM, Bastiaannet E, van de Water W, de Glas NA, et al
    Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial.
    Eur J Cancer. 2018;99:1-8.
    PubMed     Text format     Abstract available


  3. MILLS MN, Yang GQ, Oliver DE, Liveringhouse CL, et al
    Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.
    Eur J Cancer. 2018;98:48-58.
    PubMed     Text format     Abstract available


    May 2018
  4. LUND E, Nakamura A, Thalabard JC
    Re: No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer Study.
    Eur J Cancer. 2018 May 11. pii: S0959-8049(18)30773.
    PubMed     Text format    


  5. ZAHL PH
    Letter comments on EJC published paper: 'No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer study'.
    Eur J Cancer. 2018 May 11. pii: S0959-8049(18)30774.
    PubMed     Text format    


  6. CRISCITIELLO C, Golshan M, Barry WT, Viale G, et al
    Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis.
    Eur J Cancer. 2018;97:1-6.
    PubMed     Text format     Abstract available


    April 2018
  7. NABIEVA N, Fehm T, Haberle L, de Waal J, et al
    Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
    Eur J Cancer. 2018;96:82-90.
    PubMed     Text format     Abstract available


  8. GOBBINI E, Ezzalfani M, Dieras V, Bachelot T, et al
    Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
    Eur J Cancer. 2018;96:17-24.
    PubMed     Text format     Abstract available


  9. MAKAMA M, Drukker CA, Rutgers EJT, Slaets L, et al
    Corrigendum to "An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint((R)))" [Eur J Cancer 75 (April 2017) 5-13].
    Eur J Cancer. 2018 Apr 12. pii: S0959-8049(18)30747.
    PubMed     Text format    


  10. JACQUET E, Lardy-Cleaud A, Pistilli B, Franck S, et al
    Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
    Eur J Cancer. 2018;95:93-101.
    PubMed     Text format     Abstract available


  11. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
    Eur J Cancer. 2018;95:59-67.
    PubMed     Text format     Abstract available


  12. PLOQUIN A, Pistilli B, Tresch E, Frenel JS, et al
    5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.
    Eur J Cancer. 2018;95:30-37.
    PubMed     Text format     Abstract available


    March 2018
  13. RUIZ A, van Hillegersberg R, Siesling S, Castro-Benitez C, et al
    Surgical resection versus systemic therapy for breast cancer liver metastases: Results of a European case matched comparison.
    Eur J Cancer. 2018;95:1-10.
    PubMed     Text format     Abstract available


  14. ROBERTSON JFR, Cheung KL, Noguchi S, Shao Z, et al
    Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.
    Eur J Cancer. 2018;94:206-215.
    PubMed     Text format     Abstract available


  15. ETHIER JL, Ocana A, Rodriguez Lescure A, Ruiz A, et al
    Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.
    Eur J Cancer. 2018;94:199-205.
    PubMed     Text format     Abstract available


  16. LINDMAN H, Andersson M, Ahlgren J, Balslev E, et al
    A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1).
    Eur J Cancer. 2018;94:79-86.
    PubMed     Text format     Abstract available


  17. WILSON C, Bell R, Hinsley S, Marshall H, et al
    Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study.
    Eur J Cancer. 2018;94:70-78.
    PubMed     Text format     Abstract available


    February 2018
  18. PIVOT X, Bondarenko I, Nowecki Z, Dvorkin M, et al
    A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
    Eur J Cancer. 2018;93:19-27.
    PubMed     Text format     Abstract available


  19. LOKE SY, Lee ASG
    The future of blood-based biomarkers for the early detection of breast cancer.
    Eur J Cancer. 2018;92:54-68.
    PubMed     Text format     Abstract available


    January 2018
  20. RAPHAEL J, Desautels D, Pritchard KI, Petkova E, et al
    Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2018;91:38-46.
    PubMed     Text format     Abstract available


  21. BRIER MJ, Chambless DL, Chen J, Mao JJ, et al
    Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
    Eur J Cancer. 2018 Jan 9. pii: S0959-8049(17)31485.
    PubMed     Text format     Abstract available


    December 2017
  22. DACKUS GMHE, Jozwiak K, Sonke GS, van der Wall E, et al
    Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Eur J Cancer. 2017;90:92-101.
    PubMed     Text format     Abstract available


  23. ANDERSON JJ, Darwis NDM, Mackay DF, Celis-Morales CA, et al
    Red and processed meat consumption and breast cancer: UK Biobank cohort study and meta-analysis.
    Eur J Cancer. 2017;90:73-82.
    PubMed     Text format     Abstract available


  24. STRASSER-WEIPPL K, Sudan G, Ramjeesingh R, Shepherd LE, et al
    Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.
    Eur J Cancer. 2017;90:19-25.
    PubMed     Text format     Abstract available


  25. LUND E, Nakamura A, Thalabard JC
    No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer study.
    Eur J Cancer. 2017;89:102-112.
    PubMed     Text format     Abstract available


  26. NIXON NA, Hannouf MB, Verma S
    A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer.
    Eur J Cancer. 2017;89:72-81.
    PubMed     Text format     Abstract available


  27. FUJII T, Matsuda N, Kono M, Harano K, et al
    Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer.
    Eur J Cancer. 2017;89:64-71.
    PubMed     Text format     Abstract available


  28. BOTTERI E, Krendyukov A, Curigliano G
    Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
    Eur J Cancer. 2017;89:49-55.
    PubMed     Text format     Abstract available


  29. DI COSIMO S, Campbell C, Azim HA Jr, Galli G, et al
    The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.
    Eur J Cancer. 2017;89:42-48.
    PubMed     Text format     Abstract available


  30. TONG Y, Chen X, Fei X, Lin L, et al
    Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?
    Eur J Cancer. 2017;89:9-18.
    PubMed     Text format     Abstract available


  31. SCHNEEWEISS A, Chia S, Hickish T, Harvey V, et al
    Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positiv
    Eur J Cancer. 2017;89:27-35.
    PubMed     Text format     Abstract available


  32. HOLM-RASMUSSEN EV, Jensen MB, Balslev E, Kroman N, et al
    The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study.
    Eur J Cancer. 2017;87:1-9.
    PubMed     Text format     Abstract available


    November 2017
  33. DUFFY SW, Morrish OWE, Allgood PC, Black R, et al
    Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer.
    Eur J Cancer. 2017;88:48-56.
    PubMed     Text format     Abstract available


  34. MUSOLINO A, Falcini F, Sikokis A, Boggiani D, et al
    Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study.
    Eur J Cancer. 2017;88:10-20.
    PubMed     Text format     Abstract available


  35. MARTIN TA, Watkins G, Mansel RE, Jiang WG, et al
    Corrigendum to "Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer" [Eur J Cancer 40 (18) (2004) 2717-2725].
    Eur J Cancer. 2017 Nov 23. pii: S0959-8049(17)31384.
    PubMed     Text format    


  36. MILES D, Cameron D, Hilton M, Garcia J, et al
    Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer.
    Eur J Cancer. 2017 Nov 23. pii: S0959-8049(17)31358.
    PubMed     Text format    


  37. CRISCITIELLO C, Bagnardi V, Pruneri G, Vingiani A, et al
    Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer.
    Eur J Cancer. 2017;87:164-171.
    PubMed     Text format     Abstract available


  38. ANDERSON RA, Mansi J, Coleman RE, Adamson DJA, et al
    The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
    Eur J Cancer. 2017;87:58-64.
    PubMed     Text format     Abstract available


  39. FORISSIER V, Tallet A, Cohen M, Classe JM, et al
    Is post-mastectomy radiation therapy contributive in pN0-1mi breast cancer patients? Results of a French multi-centric cohort.
    Eur J Cancer. 2017;87:47-57.
    PubMed     Text format     Abstract available


  40. LE RHUN E, Bertrand N, Dumont A, Tresch E, et al
    Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
    Eur J Cancer. 2017 Nov 2. pii: S0959-8049(17)31346.
    PubMed     Text format     Abstract available


  41. DAROLES J, Borget I, Suciu V, Mazouni C, et al
    Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful?
    Eur J Cancer. 2017;85:23-30.
    PubMed     Text format     Abstract available


  42. VAN DAM PA, Tomatis M, Marotti L, Heil J, et al
    Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres.
    Eur J Cancer. 2017;85:15-22.
    PubMed     Text format     Abstract available


    October 2017
  43. PARK YH, Im SA, Kim SB, Sohn JH, et al
    Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
    Eur J Cancer. 2017;86:385-393.
    PubMed     Text format     Abstract available


  44. BIGANZOLI E, Desmedt C, Fornili M, de Azambuja E, et al
    Recurrence dynamics of breast cancer according to baseline body mass index.
    Eur J Cancer. 2017;87:10-20.
    PubMed     Text format     Abstract available


  45. VAN MAAREN MC, van Steenbeek CD, Pharoah PDP, Witteveen A, et al
    Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population.
    Eur J Cancer. 2017;86:364-372.
    PubMed     Text format     Abstract available


  46. MULLOOLY M, Murphy J, Gierach GL, Walsh PM, et al
    Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004-2013): Amassing data from independent Western populations provide etiologic clues.
    Eur J Cancer. 2017;86:326-333.
    PubMed     Text format     Abstract available


  47. TANG SS, Kaptanis S, Haddow JB, Mondani G, et al
    Current margin practice and effect on re-excision rates following the publication of the SSO-ASTRO consensus and ABS consensus guidelines: a national prospective study of 2858 women undergoing breast-conserving therapy in the UK and Ireland.
    Eur J Cancer. 2017;84:315-324.
    PubMed     Text format     Abstract available


  48. STROM T, Harrison LB, Giuliano AR, Schell MJ, et al
    Tumour radiosensitivity is associated with immune activation in solid tumours.
    Eur J Cancer. 2017;84:304-314.
    PubMed     Text format     Abstract available


  49. DE NONNEVILLE A, Goncalves A, Zemmour C, Cohen M, et al
    Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    Eur J Cancer. 2017;84:34-43.
    PubMed     Text format     Abstract available


    September 2017
  50. PIVOT X, Verma S, Fallowfield L, Muller V, et al
    Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
    Eur J Cancer. 2017;86:82-90.
    PubMed     Text format     Abstract available


  51. BIGANZOLI L, Marotti L, Hart CD, Cataliotti L, et al
    Quality indicators in breast cancer care: An update from the EUSOMA working group.
    Eur J Cancer. 2017;86:59-81.
    PubMed     Text format     Abstract available


  52. GUERIN M, Rezai K, Isambert N, Campone M, et al
    PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Eur J Cancer. 2017;86:28-36.
    PubMed     Text format     Abstract available


  53. RAPHAEL J, Helou J, Pritchard KI, Naimark DM, et al
    Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
    Eur J Cancer. 2017;85:146-154.
    PubMed     Text format     Abstract available


  54. LOIBL S, de la Pena L, Nekljudova V, Zardavas D, et al
    Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
    Eur J Cancer. 2017;85:133-145.
    PubMed     Text format     Abstract available


  55. PHI XA, Houssami N, Hooning MJ, Riedl CC, et al
    Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis.
    Eur J Cancer. 2017;85:31-38.
    PubMed     Text format     Abstract available


  56. PULITI D, Bucchi L, Mancini S, Paci E, et al
    Corrigendum to "Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy" [Eur J Cancer 75 (April 2017) 109-116].
    Eur J Cancer. 2017 Sep 2. pii: S0959-8049(17)31218.
    PubMed     Text format    


  57. LIGHTOWLERS SV, Boersma LJ, Fourquet A, Kirova YM, et al
    Preoperative breast radiation therapy: Indications and perspectives.
    Eur J Cancer. 2017;82:184-192.
    PubMed     Text format     Abstract available


  58. MUCHOWICZ A, Wachowska M, Stachura J, Tonecka K, et al
    Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice.
    Eur J Cancer. 2017;83:19-27.
    PubMed     Text format     Abstract available


  59. XIE ZM, Sun J, Hu ZY, Wu YP, et al
    Survival outcomes of patients with lobular carcinoma in situ who underwent bilateral mastectomy or partial mastectomy.
    Eur J Cancer. 2017;82:6-15.
    PubMed     Text format     Abstract available


  60. LAVOIE JM, Gelmon KA
    Getting under the skin.
    Eur J Cancer. 2017;82:228-229.
    PubMed     Text format    


    August 2017
  61. FREDHOLM H, Magnusson K, Lindstrom LS, Tobin NP, et al
    Breast cancer in young women and prognosis: How important are proliferation markers?
    Eur J Cancer. 2017;84:278-289.
    PubMed     Text format     Abstract available


  62. SCHREUDER K, Kuijer A, Rutgers EJT, Smorenburg CH, et al
    Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area.
    Eur J Cancer. 2017;84:270-277.
    PubMed     Text format     Abstract available


  63. FOCKE CM, Burger H, van Diest PJ, Finsterbusch K, et al
    Interlaboratory variability of Ki67 staining in breast cancer.
    Eur J Cancer. 2017;84:219-227.
    PubMed     Text format     Abstract available


  64. PETRELLI F, Ghidini M, Lonati V, Tomasello G, et al
    The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
    Eur J Cancer. 2017;84:141-148.
    PubMed     Text format     Abstract available


  65. SIMIN J, Tamimi R, Lagergren J, Adami HO, et al
    Menopausal hormone therapy and cancer risk: An overestimated risk?
    Eur J Cancer. 2017;84:60-68.
    PubMed     Text format     Abstract available


  66. VRIENS IJH, Keymeulen K, Lobbes MBI, van Bommel ACM, et al
    Breast magnetic resonance imaging use in patients undergoing neoadjuvant chemotherapy is associated with less mastectomies in large ductal cancers but not in lobular cancers.
    Eur J Cancer. 2017;81:74-80.
    PubMed     Text format     Abstract available


    July 2017
  67. KUMMEL S, Paepke S, Huober J, Schem C, et al
    Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
    Eur J Cancer. 2017;84:1-8.
    PubMed     Text format     Abstract available


  68. BARINOFF J, Schmidt M, Schneeweiss A, Schoenegg W, et al
    Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgery.
    Eur J Cancer. 2017;83:116-124.
    PubMed     Text format     Abstract available


  69. DIMITROVA N, Znaor A, Agius D, Eser S, et al
    Breast cancer in South-Eastern European countries since 2000: Rising incidence and decreasing mortality at young and middle ages.
    Eur J Cancer. 2017;83:43-55.
    PubMed     Text format     Abstract available


  70. BARTLETT JMS, Ahmed I, Regan MM, Sestak I, et al
    HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
    Eur J Cancer. 2017;79:129-138.
    PubMed     Text format     Abstract available


  71. ONEGA T, Weaver DL, Frederick PD, Allison KH, et al
    The diagnostic challenge of low-grade ductal carcinoma in situ.
    Eur J Cancer. 2017;80:39-47.
    PubMed     Text format     Abstract available


    June 2017
  72. SAGUATTI G, Naldoni C, Benelli E, Fedato C, et al
    Letter to the Editor regarding the paper by F. Cardoso et al. 'European Breast Cancer Conference manifesto on breast centres/units'.
    Eur J Cancer. 2017 Jun 26. pii: S0959-8049(17)31004.
    PubMed     Text format    


  73. HONG N, Yoon HG, Seo DH, Park S, et al
    Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
    Eur J Cancer. 2017;82:103-114.
    PubMed     Text format     Abstract available


  74. PIVOT X, Spano JP, Espie M, Cottu P, et al
    Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.
    Eur J Cancer. 2017 Jun 22. pii: S0959-8049(17)30960.
    PubMed     Text format     Abstract available


  75. GLIGOROV J, Ataseven B, Verrill M, De Laurentiis M, et al
    Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
    Eur J Cancer. 2017 Jun 15. pii: S0959-8049(17)30961.
    PubMed     Text format     Abstract available


  76. PIVOT X, Fumoleau P, Pierga JY, Delaloge S, et al
    Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.
    Eur J Cancer. 2017;81:151-160.
    PubMed     Text format     Abstract available


  77. BOERMAN LM, Maass SWMC, van der Meer P, Gietema JA, et al
    Long-term outcome of cardiac function in a population-based cohort of breast cancer survivors: A cross-sectional study.
    Eur J Cancer. 2017;81:56-65.
    PubMed     Text format     Abstract available


    May 2017
  78. LYNGE E, Beau AB, Christiansen P, von Euler-Chelpin M, et al
    Overdiagnosis in breast cancer screening: The impact of study design and calculations.
    Eur J Cancer. 2017;80:26-29.
    PubMed     Text format     Abstract available


  79. GILLON P, Touati N, Breton-Callu C, Slaets L, et al
    Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study.
    Eur J Cancer. 2017;79:226-234.
    PubMed     Text format     Abstract available


  80. KERBRAT P, Desmoulins I, Roca L, Levy C, et al
    Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).
    Eur J Cancer. 2017;79:166-175.
    PubMed     Text format     Abstract available


  81. SCHRAA SJ, Frerichs KA, Agterof MJ, Hunting JCB, et al
    Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice.
    Eur J Cancer. 2017;79:152-157.
    PubMed     Text format     Abstract available


  82. SCHRODER J, Fietz T, Kohler A, Petersen V, et al
    Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study.
    Eur J Cancer. 2017;79:139-148.
    PubMed     Text format     Abstract available


  83. AALDERS KC, Kuijer A, Straver ME, Slaets L, et al
    Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
    Eur J Cancer. 2017;79:98-105.
    PubMed     Text format     Abstract available


    April 2017
  84. DEZELLUS A, Barriere P, Campone M, Lemanski C, et al
    Prospective evaluation of serum anti-Mullerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
    Eur J Cancer. 2017;79:72-80.
    PubMed     Text format     Abstract available


  85. VAN NIJNATTEN TJA, Moossdorff M, de Munck L, Goorts B, et al
    TNM classification and the need for revision of pN3a breast cancer.
    Eur J Cancer. 2017;79:23-30.
    PubMed     Text format     Abstract available


  86. COLES CE, Fourquet A, Poortmans P
    Preoperative radiation therapy: The 'new' targeted breast cancer treatment?
    Eur J Cancer. 2017;78:116-117.
    PubMed     Text format    


  87. VAN ERKELENS A, Sie AS, Manders P, Visser A, et al
    Online self-test identifies women at high familial breast cancer risk in population-based breast cancer screening without inducing anxiety or distress.
    Eur J Cancer. 2017;78:45-52.
    PubMed     Text format     Abstract available


  88. ENGELHARDT EG, van den Broek AJ, Linn SC, Wishart GC, et al
    Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.
    Eur J Cancer. 2017;78:37-44.
    PubMed     Text format     Abstract available


  89. MANNU GS, Dodwell D
    Making progress in early breast cancer: Taking time or accepting risk?
    Eur J Cancer. 2017;78:24-27.
    PubMed     Text format     Abstract available


  90. KOSMIN M, Makris A, Joshi PV, Ah-See ML, et al
    The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer.
    Eur J Cancer. 2017;77:109-116.
    PubMed     Text format     Abstract available


    March 2017
  91. TWELVES C, Cortes J, O'Shaughnessy J, Awada A, et al
    Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Eur J Cancer. 2017;76:205-215.
    PubMed     Text format     Abstract available


  92. NATORI A, Ethier JL, Amir E, Cescon DW, et al
    Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
    Eur J Cancer. 2017;77:40-47.
    PubMed     Text format     Abstract available


  93. VERMEULEN MA, Slaets L, Cardoso F, Giordano SH, et al
    Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
    Eur J Cancer. 2017 Mar 11. pii: S0959-8049(17)30726.
    PubMed     Text format     Abstract available


  94. GIACCHETTI S, Hamy AS, Delaloge S, Brain E, et al
    Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Eur J Cancer. 2017;75:323-332.
    PubMed     Text format     Abstract available


  95. RIET FG, Fayard F, Arriagada R, Santos MA, et al
    Preoperative radiotherapy in breast cancer patients: 32 years of follow-up.
    Eur J Cancer. 2017;76:45-51.
    PubMed     Text format     Abstract available


  96. VAN RAMSHORST MS, van Werkhoven E, Mandjes IA, Schot M, et al
    Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.
    Eur J Cancer. 2017;74:47-54.
    PubMed     Text format     Abstract available


  97. LEONE JP, Leone J, Zwenger AO, Iturbe J, et al
    Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Eur J Cancer. 2017;74:17-25.
    PubMed     Text format     Abstract available


    February 2017
  98. AMBATIPUDI S, Horvath S, Perrier F, Cuenin C, et al
    DNA methylome analysis identifies accelerated epigenetic ageing associated with postmenopausal breast cancer susceptibility.
    Eur J Cancer. 2017;75:299-307.
    PubMed     Text format     Abstract available


  99. DUFFY MJ, Harbeck N, Nap M, Molina R, et al
    Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
    Eur J Cancer. 2017;75:284-298.
    PubMed     Text format     Abstract available


  100. VAN KAMPEN RJ, Ramaekers BL, Lobbezoo DJ, de Boer M, et al
    Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
    Eur J Cancer. 2017 Feb 25. pii: S0959-8049(17)30088.
    PubMed     Text format     Abstract available


  101. YOUSSEF MM, Cameron D, Olsen S, Ferguson D, et al
    Does axillary lymph node dissection impact survival in patients with breast cancer and isolated tumour cells or micrometastasis in sentinel node?
    Eur J Cancer. 2017;75:167-168.
    PubMed     Text format    


  102. PULITI D, Bucchi L, Mancini S, Paci E, et al
    Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy.
    Eur J Cancer. 2017;75:109-116.
    PubMed     Text format     Abstract available


  103. MAKAMA M, Drukker CA, Rutgers EJ, Slaets L, et al
    An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint(R)).
    Eur J Cancer. 2017;75:5-13.
    PubMed     Text format     Abstract available


    January 2017
  104. FREOUR T, Barriere P, Masson D
    Anti-mullerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
    Eur J Cancer. 2017;74:1-8.
    PubMed     Text format     Abstract available


  105. CARDOSO F, Cataliotti L, Costa A, Knox S, et al
    European Breast Cancer Conference manifesto on breast centres/units.
    Eur J Cancer. 2017;72:244-250.
    PubMed     Text format     Abstract available


  106. WU H, Wang D, Ruan X
    Physical activity and survival in breast cancer: What were missing?
    Eur J Cancer. 2017;71:121-122.
    PubMed     Text format    


  107. AMMITZBOLL G, Sogaard K, Karlsen RV, Tjonneland A, et al
    Reply to the letter: 'Physical activity and survival in breast cancer: What were missing?' by Wu H, Wang D, and Ruan X.
    Eur J Cancer. 2017;71:123-124.
    PubMed     Text format    


    December 2016
  108. GENRE L, Roche H, Varela L, Kanoun D, et al
    External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis.
    Eur J Cancer. 2016;72:200-209.
    PubMed     Text format     Abstract available


  109. TOUATI N, Tryfonidis K, Caramia F, Bonnefoi H, et al
    Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.
    Eur J Cancer. 2016;72:95-102.
    PubMed     Text format     Abstract available


  110. LIU CY, Huang TT, Huang CT, Hu MH, et al
    EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells.
    Eur J Cancer. 2016;72:112-123.
    PubMed     Text format     Abstract available


  111. O'BRYAN S, Dong S, Mathis JM, Alahari SK, et al
    The roles of oncogenic miRNAs and their therapeutic importance in breast cancer.
    Eur J Cancer. 2016;72:1-11.
    PubMed     Text format     Abstract available


    November 2016
  112. SUTHERLAND S, Miles D, Makris A
    Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer.
    Eur J Cancer. 2016 Nov 12. pii: S0959-8049(16)32450.
    PubMed     Text format     Abstract available


  113. MA Y, Zhang S, Zang L, Li J, et al
    Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
    Eur J Cancer. 2016;69:86-101.
    PubMed     Text format     Abstract available


  114. HEIL J, Schaefgen B, Sinn P, Richter H, et al
    Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?
    Eur J Cancer. 2016;69:142-150.
    PubMed     Text format     Abstract available


  115. OULDAMER L, Bendifallah S, Chas M, Boivin L, et al
    Intrinsic and extrinsic flaws of the nomogram predicting bone-only metastasis in women with early breast cancer: An external validation study.
    Eur J Cancer. 2016;69:102-109.
    PubMed     Text format     Abstract available


  116. MILES D, Cameron D, Bondarenko I, Manzyuk L, et al
    Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
    Eur J Cancer. 2016 Nov 4. pii: S0959-8049(16)32470.
    PubMed     Text format     Abstract available


    October 2016
  117. JERZAK KJ, Pritchard KI
    The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?
    Eur J Cancer. 2016;68:173-175.
    PubMed     Text format    


    September 2016
  118. ABDEL-QADIR H, Amir E, Fischer HD, Fu L, et al
    The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
    Eur J Cancer. 2016;68:11-21.
    PubMed     Text format     Abstract available


  119. BOUDIN L, Chabannon C, Sfumato P, Sabatier R, et al
    Corrigendum to "Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation" [Eur J Cancer 57 (April 2016) 118-126].
    Eur J Cancer. 2016 Sep 24. pii: S0959-8049(16)32402.
    PubMed     Text format    


  120. KILLANDER F, Karlsson P, Anderson H, Mattsson J, et al
    No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT.
    Eur J Cancer. 2016;67:57-65.
    PubMed     Text format     Abstract available


    August 2016
  121. NAGRANI R, Mhatre S, Rajaraman P, Soerjomataram I, et al
    Central obesity increases risk of breast cancer irrespective of menopausal and hormonal receptor status in women of South Asian Ethnicity.
    Eur J Cancer. 2016;66:153-161.
    PubMed     Text format     Abstract available


  122. ALBANELL J, Svedman C, Gligorov J, Holt SD, et al
    Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breas
    Eur J Cancer. 2016;66:104-113.
    PubMed     Text format     Abstract available


  123. TATE SC, Andre V, Enas N, Ribba B, et al
    Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
    Eur J Cancer. 2016;66:95-103.
    PubMed     Text format     Abstract available


  124. AMMITZBOLL G, Sogaard K, Karlsen RV, Tjonneland A, et al
    Physical activity and survival in breast cancer.
    Eur J Cancer. 2016;66:67-74.
    PubMed     Text format     Abstract available


    June 2016
  125. VON MINCKWITZ G, Rezai M, Tesch H, Huober J, et al
    Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).
    Eur J Cancer. 2016;64:12-21.
    PubMed     Text format     Abstract available


  126. MARGUET S, Mazouni C, Ramaekers BL, Dunant A, et al
    European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.
    Eur J Cancer. 2016;63:168-179.
    PubMed     Text format     Abstract available


  127. AALDERS KC, van Bommel AC, van Dalen T, Sonke GS, et al
    Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer.
    Eur J Cancer. 2016;63:118-126.
    PubMed     Text format     Abstract available


  128. IGNATIADIS M, Rack B, Rothe F, Riethdorf S, et al
    Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.
    Eur J Cancer. 2016;63:97-104.
    PubMed     Text format     Abstract available


    May 2016
  129. JACKISCH C, Hegg R, Stroyakovskiy D, Ahn JS, et al
    HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
    Eur J Cancer. 2016;62:62-75.
    PubMed     Text format     Abstract available


  130. SIA J, Moodie K, Bressel M, Lau E, et al
    A prospective study comparing digital breast tomosynthesis with digital mammography in surveillance after breast cancer treatment.
    Eur J Cancer. 2016;61:122-127.
    PubMed     Text format     Abstract available


  131. MACDONALD KV, Bombard Y, Deal K, Trudeau M, et al
    The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy.
    Eur J Cancer. 2016;61:85-93.
    PubMed     Text format     Abstract available


  132. GOODWIN RA, Jamal R, Booth CM, Goss PE, et al
    Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17.
    Eur J Cancer. 2016;58:97-103.
    PubMed     Text format     Abstract available


  133. HOUVENAEGHEL G, Classe JM, Garbay JR, Giard S, et al
    Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
    Eur J Cancer. 2016;58:73-82.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: